BioXcel Therapeutics, Inc. Income Statement
BTAI|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
BioXcel Therapeutics, Inc. reported $642,000 in revenue and $70M in net loss for FY2025. Revenue has grown at a 19.6% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $642.0K | $1.4M | $375.0K | $375.0K |
| Cost of Revenue | $164.0K | $1.3M | $20.0K | $20.0K |
| SG&A Expense | $20.5M | $83.4M | $68.8M | $54.2M |
| R&D Expense | $30.3M | $84.3M | $91.2M | $52.7M |
| Operating Income | -$50.5M | -$171.8M | -$159.6M | -$106.9M |
| Interest Expense | $15.3M | $11.9M | $8.2M | $40.0K |
| Income Tax | $0 | $0 | - | - |
| Net Income | -$69.9M | -$179.1M | -$165.8M | -$106.9M |
| EPS (Basic) | -$23.51 | -$98.33 | -$5.92 | -$4.05 |
| EPS (Diluted) | -$23.51 | -$98.33 | -$5.92 | -$4.05 |
| Shares Outstanding | 3.1M | 1.9M | 28.1M | 28.0M |
| Operating Margin | -7860.0% | -12448.0% | -42572.0% | -28516.0% |
| Profit Margin | -10887.4% | -12974.9% | -44201.9% | -28514.9% |